Technetium (99mTc) tilmanocept

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Technetium (99mTc) tilmanocept
Technetium-99m tilmanocept.svg
Systematic (IUPAC) name
Dextran 3-[(2-aminoethyl)thio]propyl 17-carboxy-10,13,16-tris(carboxymethyl)-8-oxo-4-thia-7,10,13,16-tetraazaheptadec-1-yl 3-[[2-[[1-imino-2-(D-mannopyranosylthio)ethyl]amino]ethyl]thio]propyl ether technetium-99m complexes
Clinical data
Trade names Lymphoseek
AHFS/Drugs.com entry
Pregnancy cat.
Legal status
Routes Intradermal, subcutaneous
Pharmacokinetic data
Half-life 1.75 to 3.05 hours at injection site
Identifiers
ATC code V09IA09
Chemical data
Formula (C6H10O5)n(C19H28N4O9S99mTc)3–8(C13H24N2O5S2)12–20(C5H11NS)0–17
Mol. mass 15,281–23,454 g/mol[1]

Technetium (99mTc) tilmanocept, trade name Lymphoseek, is a radiopharmaceutical diagnostic imaging agent approved by the U.S. Food and Drug Administration (FDA) for the imaging of lymph nodes.[1][2] It is used to locate those lymph nodes which may be draining from tumors, and assist doctors in locating those lymph nodes for removal during surgery.[3]

References[edit]

  1. ^ a b FDA Professional Drug Information
  2. ^ http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm343525.htm
  3. ^ Marcinow, A. M.; Hall, N.; Byrum, E.; Teknos, T. N.; Old, M. O.; Agrawal, A. (2013). "Use of a novel receptor-targeted (CD206) radiotracer, 99mTc-tilmanocept, and SPECT/CT for sentinel lymph node detection in oral cavity squamous cell carcinoma: Initial institutional report in an ongoing phase 3 study". JAMA otolaryngology-- head & neck surgery 139 (9): 895–902. doi:10.1001/jamaoto.2013.4239. PMID 24051744.  edit